AB

ABION Inc.

Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.

203400 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로 242 한화비즈메트로1차 242915호, 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

ABION Inc. is a clinical-stage biopharmaceutical company pioneering the development of innovative, first-in-class and best-in-class therapeutics. The company's research and development efforts are primarily focused on oncology and viral infectious diseases. Its lead oncology candidate, ABN401, is a targeted c-Met tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) that has demonstrated a superior safety profile in clinical trials. The pipeline also includes ABN501, a novel Claudin-3 targeting monoclonal antibody for various cancers. In its infectious disease program, ABION is developing ABN101, a second-generation Interferon-β inhaler as a broad-spectrum anti-viral therapy for respiratory infections. The company aims to address significant unmet medical needs through internationally recognized clinical processes for eventual global commercialization.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ABION Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 126.5 KB
2025-09-16 00:00
Related Party Transaction
[기재정정]타법인주식및출자증권처분결정
Korean 12.3 KB
2025-09-12 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.9 KB
2025-09-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 126.5 KB
2025-09-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유무상증자결정)
Korean 52.8 KB
2025-09-12 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.11)
Korean 3.5 MB
2025-09-09 00:00
Capital/Financing Update
단기차입금증가결정
Korean 9.6 KB

Automate Your Workflow. Get a real-time feed of all ABION Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ABION Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PRAP Japan,Inc. Logo
A PR & communications firm building brand reputation for corporate clients in diverse industries.
Japan 2449
Psomagen, Inc. Logo
A CRO providing multiomics services & data analysis for academic, biotech, and pharma researchers.
United States of America 950200
Public Policy Holding Company, Inc. Logo
Advisory group providing public policy, government relations, and strategic communications services.
United States of America PPHC.L
Purple Biotech Ltd. Logo
Developing cancer therapies to overcome tumor immune evasion and drug resistance.
Israel PPBT
QUIA PHARMA AB Logo
Develops biobetters by enhancing approved drugs with a patented drug delivery platform.
Sweden QUIA
Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea 115180
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan 4579
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan 6098
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan 4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan 6045

Talk to a Data Expert

Have a question? We'll get back to you promptly.